Biotech stocks in focus (JNCE, RMTI, CORV, XXII, DVAX, LCI)

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Hard for bulls to win on a morning like today and hard for bears as well, just a tricky day of price action for Wall Street. Biotech stocks somehow manage to not get affected with this Iran crisis. Biotech Catalyst Swing Names that look primed for a rally:

Jounce Therapeutics (JNCE)

Catalyst Dates: New Phase 1/2 cancer dated to be presented on February 6th

Rockwell Medical (RMTI)

Catalyst Dates: FDA Approval date of March 28th

Correvio Pharma (CORV)

Catalyst Dates: FDA Approval Date of April 27th with partner UTHR

22nd Century Group (XXII)

Catalyst Dates: Advisory Panel on February 14th

Dynavax (DVAX)

Catalyst Dates: Possible european CHMP decision coming in January 

Lannett Company (LCI)

Catalyst Dates: Possible FDA approval coming Early 2020